Treatment with intraventricular HER2-directed CAR T-cell therapy, with or without lymphodepletion (LD), was safe and led to stable disease (SD) in patients with HER2-positive breast cancer with recurrent brain and/or leptomeningeal metastases,…
CAR T-Cell Therapy Shows Early Safety in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer
